Australia markets closed

SNY Sep 2024 35.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.30000.0000 (0.00%)
As of 10:02AM EDT. Market open.
Full screen
Previous close0.3000
Open0.3000
Bid0.0000
Ask0.4500
Strike35.00
Expiry date2024-09-20
Day's range0.3000 - 0.3000
Contract rangeN/A
Volume1
Open interest6
  • Yahoo Finance Video

    Novavax-Sanofi vaccine deal, Yelp and Sweetgreen earnings: Morning Brief

    On today's episode of The Morning Brief, Hosts Seana Smith and Brad Smith break down some of the biggest news affecting the market (^DJI, ^IXIC, ^GSPC). President Biden is reportedly set to release a new wave of tariffs targeting China in critical sectors, including electric vehicles, semiconductors, and solar equipment. Novavax (NVAX) shares skyrocket following the announcement of a $1.2 billion deal with Sanofi (SNY) to commercialize its combined COVID-19 and flu shot. Restaurant and business review platform Yelp (YELP) misses first-quarter earnings estimates as US consumer spending remains relatively weak. Taiwan Semiconductor (TSM) sales jumped nearly 60% year-over-year as the artificial intelligence race heats up and demand for chips rises. Wedbush Securities Managing Director Dan Ives joins Yahoo Finance to discuss "the fourth Industrial Revolution" in AI and Apple's (AAPL) position among other Big Tech competitors. Sweetgreen (SG) shares soar after topping first-quarter revenue expectations and raising its full-year guidance. CEO Jonathan Neman joins to discuss the company's plans moving forward. This post was written by Melanie Riehl

  • Investor's Business Daily

    Biotech Rockets 125% On Sanofi Covid Vaccine Agreement

    Novavax shares shot more than 125% higher Friday on news of a Covid-19 vaccine licensing agreement with Sanofi. The agreement involves co-development of Covid/flu vaccine combinations for both companies.

  • Bloomberg

    Novavax Soars on $1.2 Billion Sanofi Vaccine Licensing Deal

    (Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Most Read from BloombergBiden Set to Hit China EVs, Strategic Sectors With TariffsElon Musk Pledges to Grow Supercharger Business He Just DecimatedAckman Scolded Over DEI Views at Closed-Door Milken SessionApple Apologizes for iPad Pro Ad, Scraps Plan to Air It on TVNovavax Soars on $1.2 Billion Sanofi Vaccine Licensing